U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

New Drug Application (NDA): 208434
Company: HOFFMANN-LA ROCHE
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
ALECENSA ALECTINIB HYDROCHLORIDE EQ 150MG BASE CAPSULE;ORAL Prescription None Yes Yes
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
12/11/2015 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY; Orphan Label (PDF)
Review
Summary Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000SumR.pdf
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
04/18/2024 SUPPL-15 Efficacy-New Indication Label (PDF)
Letter (PDF)
Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/208434Orig1s015ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/208434Orig1s015MultidisciplineR.pdf
09/03/2021 SUPPL-12 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208434Orig1s012ltr.pdf
01/29/2021 SUPPL-10 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/208434Orig1s010ltr.pdf
06/05/2018 SUPPL-4 Labeling-Package Insert Label (PDF)
Letter (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208434Orig1s004ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/208434Orig1s004ltr.pdf
11/06/2017 SUPPL-3 Efficacy-New Indication Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/208434Orig1s003ltr.pdf
11/04/2016 SUPPL-1 Labeling-Package Insert Label (PDF)
Letter (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208434s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/208434Orig1s001ltr.pdf
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
04/18/2024 SUPPL-15 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208434s015lbl.pdf
09/03/2021 SUPPL-12 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s012lbl.pdf
01/29/2021 SUPPL-10 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208434s010lbl.pdf
06/05/2018 SUPPL-4 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf
11/06/2017 SUPPL-3 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf
11/04/2016 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208434s001lbl.pdf
12/11/2015 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf
Back to Top